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4Abstract60
Genetics has proven to be a powerful approach in neurodegenerative diseases research,61
resulting in the identification of numerous causal and risk variants. Previously, we introduced62
the NeuroX Illumina genotyping array, a fast and efficient genotyping platform designed for the63
investigation of genetic variation in neurodegenerative diseases. Here, we present its updated64
version, named NeuroChip. The NeuroChip is a low cost, custom-designed array containing a65
tagging variant backbone of about 306,670 variants complemented with a manually curated66
custom content comprised of 179,467 variants implicated in diverse neurological diseases,67
including Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, amyotrophic lateral68
sclerosis, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration69
and multiple system atrophy. The tagging backbone was chosen because of the low cost and70
good genome-wide resolution; the custom content can be combined with other backbones, like71
population or drug development arrays. Using the NeuroChip, we can accurately identify rare72
variants and impute over 5.3 million common SNPs from the latest release of the Haplotype73
Reference Consortium. In summary, we describe the design and usage of the NeuroChip array,74
and show its capability for detecting rare pathogenic variants in numerous neurodegenerative75
diseases. The NeuroChip has a more comprehensive and improved content, which makes it a76
reliable, high-throughput, cost-effective screening tool for genetic research and molecular77
diagnostics in neurodegenerative diseases.78
79
51. Introduction80
Neurodegenerative diseases are a major burden to the aging world population and currently81
these diseases are incurable and irreversible. Common and rare genetic alterations in many82
genes have been identified as disease-causing or contributing to the development of83
neurodegeneration (Naj et al., 2017, Singleton and Hardy, 2016). To date, there are four main84
uses of genetics: 1) to confirm a clinical diagnosis by identifying a causal mutation, 2) to identify85
risk variants and disease modifiers that influence risk for disease, 3) to increase knowledge of86
the molecular pathobiology of disease in the hopes of identifying therapeutic targets, and 4) to87
improve patient selection for pathway-specific clinical trial design. A reliable, high-throughput88
and cost-effective platform that can rapidly conduct these functions could therefore be89
immensely valuable to the field.90
Previously, we presented the NeuroX array, which was a collaborative effort with the objective91
of designing a genotyping platform that would allow rapid genetic characterization of samples92
in the context of genetic mutations and risk factors associated with common93
neurodegenerative diseases (Nalls et al., 2015). This was an exonic array (or exome chip) based94
on the Infinium HumanExome Beadchip v1.1 containing 242,901 exome-focused variants as95
well as 24,706 custom variants focusing on neurological diseases. The NeuroX array has already96
been successfully used in dozens of studies (Barber et al., 2017, Carrasquillo et al., 2016, Ghani97
et al., 2015, Nalls et al., 2016, Rosenthal et al., 2016). However, due to the backbone’s focus on98
rare exonic variation, common non-exonic variants were largely missed, resulting in a modest99
genome-wide resolution and only partial capture of the known low frequency exonic variation.100
6Additionally, the number of genotype-phenotype associations and pathogenic variants keeps101
expanding, so there was a continued need for updating this useful platform.102
Here, we report on an updated version of NeuroX, named NeuroChip. The NeuroChip backbone103
is based on a genome-wide genotyping array (Infinium HumanCore-24 v1.0) containing 306,670104
tagging variants and a custom content that has been updated and extended with105
neurodegenerative disease-related custom content consisting of 179,467 variants. This106
backbone was chosen because of the low cost and good genome-wide resolution. This107
backbone is flexible and other arrays can be used with this custom content, such as population108
or drug development arrays (Infinium Multi-Ethnic, Infinium DrugDev). The NeuroChip allows to109
accurately identify rare neurodegenerative candidate variants and impute over 5.3 million110
common variants. Its approximate cost of ~$40 per sample is a fraction of the price of next-111
generation whole exome or whole genome sequencing, and therefore provides a valuable,112
high-throughput screening tool for loci and variants implicated in neurodegenerative diseases.113
Further, this array can be used as a tool to prioritize samples for more expensive genome114
sequencing approaches.115
116
2. Methods117
2.1 NeuroChip array design118
The backbone of the array, the Infinium HumanCore-24 v1.0, contains 306,670 highly119
informative tagging SNPs which can be used for high-throughput and high-quality imputation of120
genome-wide variants across diverse populations (Illumina). In addition, the chip contains121
179,467 custom disease-associated variants (Table 1) covering neurodegenerative diseases122
7including: Alzheimer’s disease (AD), Parkinson’s disease (PD), Lewy body dementia (LBD),123
frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), progressive supranuclear124
palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). The custom-125
content has been curated by members of the International Parkinson’s Disease Genomics126
Consortium (IPDGC) and the Comprehensive Unbiased Risk factor Assessment for Genetics and127
Environment in Parkinson disease (COURAGE-PD) consortium to include common variants and128
rare mutations implicated in neurological diseases as reported in the Human Gene Mutation129
Database (HGMD Professional 2016.4, QIAGEN), the NHGRI GWAS Catalog130
(www.ebi.ac.uk/gwas/), the Online Mendelian Inheritance in Man (OMIM) database131
(www.ncbi.nlm.nih.gov/omim/), the Parkinson’s Disease Mutation Database (www.molgen.vib-132
ua.be/PDMutDB), the Alzheimer’s Disease and Frontotemporal Dementia Database133
(www.molgen.ua.ac.be/admutations/), and based on literature review as well as own data;134
particularly in the latter case, collaborators submitted variants that were identified in multiple135
ongoing (or completed) unpublished projects, including variants from genome-wide association136
(GWA), whole exome, whole genome, targeted sequencing studies and systems biology studies.137
See Supplementary Table 1 for the complete content of the NeuroChip array.138
139
2.2 NeuroChip array genotyping140
We genotyped a cohort of 273 controls as per the manufacturer's instructions (Illumina) to141
generate pilot NeuroChip data. These samples have been collected by the North American Brain142
Expression Consortium (NABEC) and described elsewhere (Hernandez et al., 2012). In total, 183143
males and 90 females were included. All samples were obtained from North American brain144
8banks and subjects reported European ancestry and had no reported neurological disease. To145
assess the reproducibility of the NeuroChip, we genotyped 15 samples twice in separate146
experiments.147
Raw data files were imported into GenomeStudio (version 2.0, Illumina). For initial quality148
control, we confirmed accurate, high quality genotyping using a call rate threshold of > 95%.149
We reclustered the samples using a GenCall threshold of 0.15 and recalled all variants. The150
genotyping cluster file based on ~3,500 individuals of ongoing projects is available in the151
Supplementary Materials (Supplementary File 1). The mean call rate post-reclustering was152
0.992 (range: 0.954-0.995). The data were exported from GenomeStudio using the Illumina-to-153
PLINK module 2.1.4 and imported into PLINK (version 1.90) (Chang et al., 2015). Next, we154
checked individuals for discrepancies between reported sex and genotypic sex, cryptic155
relatedness (PIHAT <0.05), and heterogeneity contamination, and found that no samples failed156
this quality control step.157
158
2.3 NeuroChip content annotation159
Annotation of the NeuroChip content was performed using ANNOVAR (Wang et al., 2010). For160
each variant, a gene-based annotation, in silico impact scores, and frequencies from public161
databases were obtained. To predict the impact scores, the following algorithms were used:162
SIFT (Kumar et al., 2009), Polyphen-2 (Adzhubei et al., 2010), and CADD (Kircher et al., 2014).163
Population frequencies were obtained from the Exome Aggregation Consortium (version 0.3.1)164
(http://exac.broadinstitute.org/) containing 60,706 individuals. Additionally, all variants were165
investigated for their presence in the Human Gene Mutation Database (HGMD, accessed 20166
9December 2016). Variants associated with a common neurodegenerative syndrome (AD, ALS,167
FTD and PD) were manually curated and are summarized in Supplementary Table 2.168
169
2.4 NeuroChip content imputation170
After confirming high-quality genotyping (call rate >95%) and European ancestry in all171
individuals (based on 1000Genomes clustering) (Genomes Project et al., 2015), we performed172
imputation using the Michigan imputation server, according to established guidelines173
(https://imputationserver.sph.umich.edu) (Das et al., 2016). In brief, genotypes were prepared174
for imputation using provided scripts (HRC-1000G-check-bim.pl), which compares variant ID,175
strand, and allele frequencies to the haplotype reference panel (HRC version r1.1, April 2016)176
(McCarthy et al., 2016). A total of 332,015 autosomal SNPs were submitted to the Imputation177
Server using ShapeIT (v2.r790).178
179
2.5 APOE allele genotyping180
To determine the accuracy of APOE allele predictions, we performed Taqman genotyping of181
two nonsynonymous APOE SNPs (rs7412 and rs429358) on an Applied Biosystems ViiA 7 Real-182
Time PCR System using an established protocol (Federoff et al., 2012). 272 out of 273 control183
samples had sufficient DNA for genotyping. Allelic discrimination was conducted using184
QuantStudio software (version 1.3, Thermo Fisher Scientific, Carlsbad, CA, USA). Taqman185
genotype results were then compared to the corresponding results for the same SNPs186
generated using the NeuroChip. Given the importance of APOE, NeuroChip was designed so187
that rs7412 is genotyped by four separate probes (three of which performed well: rs7412, seq-188
10
rs7412-B1, seq-rs7412-B3). Similarly, rs429358 was genotyped by five separate bead probes189
(two of which performed well: seq-rs429358-T2, seq-rs429358-T3). This redundancy ensures190
accurate APOE genotyping by the NeuroChip platform.191
192
3. Results193
3.1 NeuroChip content overview194
In total, the NeuroChip array contains 473,442 autosomal variants, 11,840 sex chromosomal195
variants, and 160 mitochondrial variants. Additionally, 16,274 NeuroChip variants detect small196
insertions or deletions (Table 1). The overlap between NeuroX and NeuroChip is small (n=197
19,289 variants) due to the difference in the design of the backbone; the NeuroX array is198
focused on exonic content, whereas the NeuroChip is focused on genome wide tagging content.199
200
3.2 NeuroChip pathogenic variant content201
In total, the NeuroChip harbors 8,086 disease-associated variants that are included in HGMD, a202
professionally curated database of published genetic variants that have been linked to inherited203
human diseases (neurological and non-neurological). The NeuroChip HGMD content includes204
1,233 variants (1,202 SNPs and 31 indels) linked to common neurodegenerative syndromes (see205
Supplementary Figure 1 for a comparison between NeuroX and NeuroChip). In this content,206
after manually curation, 601 variants are associated with ALS or FTD, 348 with PD, and 284 with207
AD. Figure 1 shows the number of disease associated variants per gene covered in common208
neurodegenerative syndromes based on the HGMD database. Detailed, manually curated and209
annotated variant lists for the abovementioned neurodegenerative disease categories are210
11
documented in Supplementary Table 2. These annotated lists can be used as filters to quickly211
screen for known mutations and risk variants.212
213
3.3 NeuroChip genotyping results214
Genotyping reproducibility215
Of the 15 technical replicates, all samples yielded high quality, reproducible genotyping results.216
The mean concordance rate per technical replicate was 0.9996 (range=0.9991-0.9999); on217
average, 190 variants (range=27-435) differed per technical replicate (0.04% of the total218
included variants on the array). Across the 15 technical replicates, 1,978 unique variants were219
discordant, of which 749 (37.9%) were from the backbone and 1,229 (62.1%) were from the220
custom content (Supplementary Table 3).221
222
Imputation223
Imputation of autosomal variants was performed on a series of 273 European descent224
individuals using the haplotype reference panel (McCarthy et al., 2016) containing 39,235,157225
variants, all with an estimated minor allele count of >= 5 in 32,488 individuals. Initial pre-226
imputation filtering of the NeuroChip data (including removing duplicates and non-overlapping227
variants, switch strands, and updating position) resulted in 332,015 variants. After imputation,228
11,879,345 variants were obtained with an imputation R2 of > 0.30. Filtering based on MAF >229
0.05, Hardy-Weinberg Equilibrium p-value of > 1e-6 resulted in 5,316,028 variants. In this230
imputed dataset, we successfully identified 22 of 26 PD risk alleles and 19 of the 21 AD GWA231
SNPs (Lambert et al., 2013, Nalls et al., 2014).232
12
233
Genotype accuracy234
GenTrain scores were calculated for all NeuroChip variants using GenomeStudio (version 2,235
lllumina). The GenTrain score is a statistical score based on the shapes of the different allelic236
clusters and their relative distance to each other (Illumina). Typically, GenTrain scores > 0.7 are237
considered high quality genotypes. Previously, GenTrain scores of the NeuroX showed that238
genotyping quality in the custom content was lower compared to the backbone (Nalls et al.,239
2015). However, preliminary NeuroChip data from several ongoing projects (based on ~3,500240
individuals) reveals that the backbone and the custom content have a high comparable average241
score (0.819 and 0.820, respectively), indicating high genotyping accuracy (Supplementary242
Figures 2 & 3).243
244
Validation of APOE genotyping245
APOE alleles are important genetic risk factors for both AD and LBD, but genotyping of this246
region is complicated by high GC content (Singleton et al., 2002, Strittmatter and Roses, 1996).247
For this reason, we chose to validate the accuracy of APOE allele genotyping by comparing248
Taqman results with genotype predictions from the NeuroChip (Supplementary Table 4).249
Taqman genotyping for rs7412 and rs429358 was successful in all 272 samples. NeuroChip250
genotyping for both SNPs was successful in 265 out of these 272 controls. Five samples were251
discordant for APOE allele genotyping between Taqman and NeuroChip, likely due to relatively252
low quality genotype calls in either the Taqman assay or the NeuroChip, representing 1.9% of253
our test cohort (n = 265 samples). Overall, the performance of the NeuroChip for APOE254
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genotyping was significantly better than the original NeuroX platform, which was unable to255
reliably detect rs7412 and rs429358 genotypes (Ghani et al., 2015, Nalls et al., 2015).256
257
4. Discussion258
The main goal was to develop a genotyping array that allows a rapid, high-throughput259
identification of common and rare single nucleotide variants in the human genome. Affordable260
screening of large cohorts for disease-associated variants allows for testing of polygenic261
inheritance that could explain the diversity of clinical and pathological characteristics of262
neurodegenerative diseases. The NeuroChip is estimated to cost ~ $40/sample, which is263
currently less than ~ 10% and ~ 5% of the cost of whole exome sequencing and whole genome264
sequencing, respectively.265
We have designed, implemented, and validated the NeuroChip array platform for high266
throughput genotyping. However, it is important to recognize the limitations of this approach.267
Like all genotyping arrays, NeuroChip does not detect novel sequence changes. It is also not268
possible to genotype variants in complex genomic regions (e.g. due to pseudogenes) or to269
identify repeat expansions due to the difficulty in designing reliable probes. Nevertheless, every270
effort was made to improve genotyping calling in NeuroChip. For example, it was recognized271
that the APOE locus performed poorly on the original NeuroX platform (Ghani et al., 2015).272
Given the importance of this genomic region in neurodegeneration, the revised NeuroChip273
probe design included multiple probes for SNPs in this region. This led to reliable APOE allele274
calling with a concordance rate of 98.1% between NeuroChip and Taqman.275
14
In conclusion, we describe the design and implementation of the NeuroChip array, which has a276
more comprehensive and improved content compared to NeuroX. This versatile genotyping277
platform provides the community with a novel tool that can be used in both a clinical and278
research setting. In a clinical setting, it is possible to rapidly screen patients for a large number279
of known pathogenic variants and in a research setting cost-effective and high throughput280
detection of both common and rare variants gives the opportunity to perform several analyses281
including GWAS, burden tests and genetic risk scores calculations.282
283
References284
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and285
server for predicting damaging missense mutations. Nat Methods 2010;7(4):248-9.286
Barber IS, Braae A, Clement N, Patel T, Guetta-Baranes T, Brookes K, et al. Mutation analysis of287
sporadic early-onset Alzheimer's disease using the NeuroX array. Neurobiol Aging288
2017;49:215 e1- e8.289
Carrasquillo MM, Barber I, Lincoln SJ, Murray ME, Camsari GB, Khan Q, et al. Evaluating290
pathogenic dementia variants in posterior cortical atrophy. Neurobiol Aging 2016;37:38-291
44.292
Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to293
the challenge of larger and richer datasets. Gigascience 2015;4:7.294
Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, et al. Next-generation genotype295
imputation service and methods. Nat Genet 2016;48(10):1284-7.296
15
Federoff M, Jimenez-Rolando B, Nalls MA, Singleton AB. A large study reveals no association297
between APOE and Parkinson's disease. Neurobiol Dis 2012;46(2):389-92.298
Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global299
reference for human genetic variation. Nature 2015;526(7571):68-74.300
Ghani M, Lang AE, Zinman L, Nacmias B, Sorbi S, Bessi V, et al. Mutation analysis of patients301
with neurodegenerative disorders using NeuroX array. Neurobiol Aging 2015;36(1):545302
e9-14.303
Hernandez DG, Nalls MA, Moore M, Chong S, Dillman A, Trabzuni D, et al. Integration of GWAS304
SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in305
blood and brain. Neurobiol Dis 2012;47(1):20-8.306
Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for307
estimating the relative pathogenicity of human genetic variants. Nat Genet308
2014;46(3):310-5.309
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on310
protein function using the SIFT algorithm. Nat Protoc 2009;4(7):1073-81.311
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of312
74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet313
2013;45(12):1452-8.314
McCarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of315
64,976 haplotypes for genotype imputation. Nat Genet 2016;48(10):1279-83.316
16
Naj AC, Schellenberg GD, Alzheimer's Disease Genetics C. Genomic variants, genes, and317
pathways of Alzheimer's disease: An overview. Am J Med Genet B Neuropsychiatr Genet318
2017;174(1):5-26.319
Nalls MA, Bras J, Hernandez DG, Keller MF, Majounie E, Renton AE, et al. NeuroX, a fast and320
efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol321
Aging 2015;36(3):1605 e7-12.322
Nalls MA, Keller MF, Hernandez DG, Chen L, Stone DJ, Singleton AB, et al. Baseline genetic323
associations in the Parkinson's Progression Markers Initiative (PPMI). Mov Disord324
2016;31(1):79-85.325
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of326
genome-wide association data identifies six new risk loci for Parkinson's disease. Nat327
Genet 2014;46(9):989-93.328
Rosenthal LS, Drake D, Alcalay RN, Babcock D, Bowman FD, Chen-Plotkin A, et al. The NINDS329
Parkinson's disease biomarkers program. Mov Disord 2016;31(6):915-23.330
Singleton A, Hardy J. The Evolution of Genetics: Alzheimer's and Parkinson's Diseases. Neuron331
2016;90(6):1154-63.332
Singleton AB, Wharton A, O'Brien KK, Walker MP, McKeith IG, Ballard CG, et al. Clinical and333
neuropathological correlates of apolipoprotein E genotype in dementia with Lewy334
bodies. Dement Geriatr Cogn Disord 2002;14(4):167-75.335
Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci336
1996;19:53-77.337
17
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-338
throughput sequencing data. Nucleic Acids Res 2010;38(16):e164.339
340
341
